This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KIN Kindred Biosciences (KIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Kindred Biosciences Stock (NASDAQ:KIN) Get Kindred Biosciences alerts:Sign Up Key Stats Today's Range$9.24▼$9.2650-Day Range$9.08▼$9.2552-Week Range$3.46▼$9.28Volume178,496 shsAverage Volume840,890 shsMarket Capitalization$420.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA. Read More Kindred Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreKIN MarketRank™: Kindred Biosciences scored higher than 17% of companies evaluated by MarketBeat, and ranked 888th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Kindred Biosciences. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kindred Biosciences are expected to grow in the coming year, from ($0.71) to ($0.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kindred Biosciences is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kindred Biosciences is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKindred Biosciences has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for KIN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKindred Biosciences does not currently pay a dividend.Dividend GrowthKindred Biosciences does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-1.96 Short InterestThere is no current short interest data available for KIN. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for KIN on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kindred Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders13.69% of the stock of Kindred Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.89% of the stock of Kindred Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kindred Biosciences' insider trading history. Receive KIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KIN Stock News HeadlinesWhy Silicon Valley falls prey to ‘charisma distortion,’ according to investor and Google X founding member Tom ChiAugust 19, 2024 | msn.comWillow Smith announces the new release date of her first book “Black Shields Maiden”April 23, 2024 | msn.comNvidia CEO’s Regret: ‘I Wish I Gave [Elon] More’…Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Since then, we've seen a massive rollout of AI legislation, and the some of the stocks I recommended back then have doubled the market's return. Now I'm releasing a new "BUY LIST" to take advantage of Elon’s next launch, and giving away one name and ticker for free on this page here.October 16 at 2:00 AM | Altimetry (Ad)Tory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire PoliceMarch 22, 2024 | mirror.co.ukMKindred Hospital East GreensboroFebruary 22, 2024 | health.usnews.comJapan's Sony terminates $10 bln Zee India mergerJanuary 22, 2024 | reuters.comEuropean Shares Edge Higher With ECB Meeting In The SpotlightJanuary 22, 2024 | markets.businessinsider.comEarnings Optimism May Contribute To Continued Strength On Wall StreetJanuary 22, 2024 | markets.businessinsider.comSee More Headlines KIN Stock Analysis - Frequently Asked Questions How were Kindred Biosciences' earnings last quarter? Kindred Biosciences, Inc. (NASDAQ:KIN) issued its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%. What other stocks do shareholders of Kindred Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol Myers Squibb (BMY) and Meta Platforms (META). Company Calendar Last Earnings8/05/2021Today10/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:KIN CIK1561743 Webkindredbio.com Phone(650) 701-7901FaxN/AEmployees63Year Founded2013Profitability EPS (Trailing Twelve Months)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.80 million Net Margins-529.26% Pretax MarginN/A Return on Equity-54.19% Return on Assets-39.76% Debt Debt-to-Equity Ratio0.19 Current Ratio7.02 Quick Ratio7.02 Sales & Book Value Annual Sales$42.16 million Price / Sales9.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book5.29Miscellaneous Outstanding Shares45,462,000Free FloatN/AMarket Cap$420.52 million OptionableOptionable Beta1.30 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:KIN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kindred Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kindred Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
